In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Health status assessment of patients followed in a Heart Failure Clinic

Session Poster Session 2

Speaker Daniel Seabra

Event : Heart Failure 2019

  • Topic : cardiovascular nursing and allied professions
  • Sub-topic : Cardiovascular Nursing and Allied Professions - Other
  • Session type : Poster Session

Authors : P Silva (Penafiel,PT), I Oliveira (Penafiel,PT), A Neto (Penafiel,PT), D Seabra (Penafiel,PT), S Ferreira (Penafiel,PT), M Soares (Penafiel,PT), A Ferreira (Penafiel,PT), S Poaires (Penafiel,PT), M Meira (Penafiel,PT), A Andrade (Penafiel,PT)

P Silva1 , I Oliveira1 , A Neto1 , D Seabra1 , S Ferreira1 , M Soares1 , A Ferreira1 , S Poaires1 , M Meira1 , A Andrade1 , 1Hospital Centre do Tamega e Sousa - Penafiel - Portugal ,


Introduction: Heart failure (HF) is a syndrome with significant morbidity and socioeconomical impact. Health status (HS) relates to pts perception of the functional impact of symptoms in daily life. The European Quality of Life Index (EuroQol) is an internationally validated questionnaire that reflects pts insight on their HS, improving their sensitivity and understanding of the disease.

Aims: To evaluate HS and assess its variation in pts with HF followed in a HF Clinic (HFC). 

Methods: Unicentric, retrospective analysis of pts followed in a HFC since 3/2011. Included pts with diagnosis of HF for at least 1 year and with a HF hospitalization (HFH) within this period, who had completed the EuroQol questionnaire 6 months after the first nursing teaching session. EuroQoI comprises 3 components: a visual scale measured from 0 to 100, with a higher number reflecting better HS perception on the day of the appointment; a question about pts perception of their HS comparing with 1 year before; 5 main fields related to mobility, self-care, daily life activities, pain/discomfort and depression/anxiety, according to the pt status. 

Results: Included 88 pts, mostly men (78.4%), with a mean age of 60 +/-13,4 years. 65% had ischemic etiology. No significant differences in HS self-assessment were found between genders. There was an inverse correlation between HS and age. Pts living in urban areas and with higher education levels had better HS perception. The majority of pts had no limitations in the 5 fields assessed in the questionnaire. There was a high prevalence of anxiety/depression (46%), with 16% feeling extremely anxious/depressed. Regarding the visual scale, the mean HS perception in the moment of the appointment was 64.3 +/-17,59, ranging from 10 to 100. Considering the point "HS insight compared to one year before", there was an improvement in 54.5% of pts, while 16% felt worse and 29.5% had a similar HS.

Conclusion: The EuroQoI is a useful tool to help pts recognise the functional impact of their disease on daily life and its evolution over time. By assessing various fields, it highlights important areas for intervention in nursing teaching sessions, in order to improve pts overall HS and decrease HFH. In our cohort, pts had high levels of anxiety/depression, emphasizing the need to develop interventions in this area. There was also an improvement in HS insight comparing with the previous year, which may reflect the impact of HFC and nursing teaching sessions in this disease.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are